Collectively, our results provide compelling evidence that MALAT1 depletion enhances the sensitivity to PARPi; hence, targeting both simultaneously will be a promising therapeutic approach for patients with advanced stage prostate cancer, who often develop resistance to conventional therapeutic strategies. This evidence concerns the gene MALAT1 and Familial prostate cancer.